Midol Liquid Gels is a drug owned by Bionpharma Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 25, 2018. Details of Midol Liquid Gels's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6251426 | Ibuprofen-containing softgels |
Jun, 2018
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Midol Liquid Gels is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Midol Liquid Gels's family patents as well as insights into
ongoing legal events
on those patents.
Midol Liquid Gels's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Midol Liquid Gels:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Midol Liquid Gels's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 25, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Midol Liquid Gels Generic API suppliers:
Ibuprofen is the generic name for the brand Midol Liquid Gels. 68 different companies have already filed for the generic of Midol Liquid Gels, with Contract Pharmacal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Midol Liquid Gels's generic
Alternative Brands for Midol Liquid Gels
There are several other brand drugs using the same active ingredient (Ibuprofen) as Midol Liquid Gels. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Aft Pharms Us |
| |||||
| Apotex |
| |||||
| Haleon Us Holdings |
| |||||
| Hikma |
| |||||
| Horizon |
| |||||
| Kenvue Brands |
| |||||
| Recordati Rare |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ibuprofen, Midol Liquid Gels's active ingredient. Check the complete list of approved generic manufacturers for Midol Liquid Gels
About Midol Liquid Gels
Midol Liquid Gels is a drug owned by Bionpharma Inc. Midol Liquid Gels uses Ibuprofen as an active ingredient. Midol Liquid Gels was launched by Bionpharma in 2002.
Approval Date:
Midol Liquid Gels was approved by FDA for market use on 18 October, 2002.
Active Ingredient:
Midol Liquid Gels uses Ibuprofen as the active ingredient. Check out other Drugs and Companies using Ibuprofen ingredient
Dosage:
Midol Liquid Gels is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | CAPSULE | Over the counter | ORAL |